Successful treatment with Rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin's lymphoma.
Shvidel
L
L
Klepfish
A
A
Berrebi
A
A
D000310:Adrenal Gland Neoplasms; D000328:Adult; D000477:Alkylating Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D003131:Combined Modality Therapy; D004351:Drug Resistance; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D016393:Lymphoma, B-Cell / Q000097:blood / Q000150:complications / Q000276:immunology / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000150:complications / Q000276:immunology / Q000628:therapy*; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood; D009378:Neoplasms, Multiple Primary; D010673:Pheochromocytoma; D011693:Purpura / Q000209:etiology; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery; D012074:Remission Induction; D000069283:Rituximab; D013156:Splenectomy
D000477:Alkylating Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D009363:Neoplasm Proteins; D000069283:Rituximab